Opinion

Video

Recurrence Rates in Uncomplicated UTIs

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Thomas M. Hooton, MD

Panelists discuss how significant gaps in current uncomplicated urinary tract infection (UTI) therapies include insufficient nonantibiotic preventive strategies, limited options for multidrug-resistant pathogens, inadequate personalized treatment approaches, minimal focus on biofilm disruption, lack of rapid point-of-care diagnostics to guide targeted therapy, poor understanding of the urinary microbiome’s role in infection susceptibility, and insufficient research into immunomodulatory interventions that could address the underlying mechanisms of recurrence and resistance development.

Video content above is prompted by the following:

  • What gaps exist in current therapies for uncomplicated UTIs, particularly regarding the management of recurrence rates and the development of antibiotic resistance
Related Videos
4 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
4 experts are featured in this series.
Raj Chovatiya, MD, PhD, MSCI.
Galen Shearn-Nance, BS, and Johnie Rose, MD, PhD
4 experts are featured in this series.
Related Content
FDA headquarters | Image Credit: Tada Images - stock.adobe.com
April 18th 2025

5 Notable FDA Approvals From March Highlight Advancements Across Therapeutic Areas

Brooke McCormick
From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.
managed care cast logo
December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick
On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.
Patients who stopped adjuvant immunotherapy less than 12 months following metastatic melanoma resection did not experience inferior outcomes. | anna.stasiia - stock.adobe.com
April 17th 2025

Early Adjuvant Immunotherapy Discontinuation Does Not Affect Melanoma Recurrence Risk

Jared Kaltwasser
Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.
"Overactive bladder" written on sticky note | Image Credit: syahrir - stock.adobe.com
April 15th 2025

Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk

Brooke McCormick
Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.
Patient taking survey | Image Credit: terovesalainen - stock.adobe.com
April 15th 2025

EHR-Based Symptom Inventory Shows Potential for Ovarian Cancer Monitoring

Brooke McCormick
The electronic health record (EHR)–based symptom inventory identified symptom prevalence and associated comorbidities, but no ovarian cancers were diagnosed during the study period.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo